This biopharma play with two key drugs for treatment-resistant depression could see its stock rise by more than 230%, according to a Deutsche Bank analyst.
Source: US Top News and Analysis
Related Posts
Infiniti hopes new SUV can turn around fortunes in the U.S.
Infiniti is releasing a new midsize SUV, the QX65, in an effort to turn around…
Oil prices falls as Trump says Iran let 10 tankers through Hormuz as a ‘present’
Oil prices fell after Donald Trump said Iran had allowed 10 oil tankers to pass…
Expecting to fight about money with your partner? You might be wrong, study finds
People in romantic relationships tend to expect financial discussions about with their partner to go…